Latest Shareholder Engagement News

Regal Partners Global Investments Limited has updated its Dividend Reinvestment Plan to reflect its recent rebranding and remove participation barriers, effective immediately for the 1H26 interim dividend.

Kalamazoo Resources has successfully closed an oversubscribed Share Purchase Plan, raising $4.1 million to fast-track drilling and development at its Ashburton Gold Project. Combined with a recent placement, the company secures $12.1 million to advance exploration and pre-feasibility studies.

Pursuit Minerals has successfully completed the first tranche of a $7 million placement, issuing nearly 47 million shares at 9.5 cents each, with a second tranche and incentive options pending shareholder approval.

US1 Critical Minerals announces a bonus issue of options to shareholders and a $1.5 million placement with free attaching options, pending shareholder approval.

ION Video Ltd has strengthened its board with the return of its original inventor, Finbar O’Hanlon, alongside CEO Anthony Baker, as the company pivots to become foundational infrastructure for Video Superintelligence.

Krakatoa Resources has raised $1.25 million through a well-supported placement to fund the next phase of exploration at its high-grade Zopkhito Antimony-Gold Project, following promising drilling results that validate historic data.

Apiam Animal Health shareholders convened on 3 February 2026 to vote on a scheme of arrangement proposing acquisition by Adamantem Capital Fund II, with the board unanimously recommending approval. The scheme offers $0.87 cash per share or scrip alternatives, pending final court approval.

ClearVue Technologies advances its building-integrated solar tech with new product breakthroughs and global commercial projects, while strengthening its financial footing and board expertise.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

MEC Resources has bolstered its stake in Advent Energy with a $1.55 million loan while navigating a pivotal Federal Court hearing on the PEP 11 Joint Venture. Meanwhile, progress on Clean Hydrogen Technology signals potential growth avenues.

Turners Automotive Group has issued over 180,000 new shares through its Dividend Reinvestment Plan and option exercises, subtly reshaping its capital structure as FY26 progresses.